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Objectives . The aim of this study was to compare, in dogs, the
antithrombotic activity of aspirin and the murine monoclonal
antibody P37, which inhibits platelet aggregation and fibrinogen
binding to activated platelets .
Background. The andthrombotic activity of 137 has been
somewhat predictable, given its in vitro platelet antiaggregating
activity and localization at or very near the fibrinogen binding site
in the platelet fibrinogen receptor, the glycoprotein Ilb/1112 or
integrin alphallb-beta 3 .
Methods . The monoclonal antibody P37 of the immunogamma-
globulin-I isotype was prepared according to previously described
immunization and fusion protocols and screening assays . To
compare its antiaggregating capacity with that of aspirin, exper-
imental thrombosis was induced in all dogs by means of direct
current applied to the carotid artery . Autologous platelets had
Despite the use of antithrombotic agents, acute thrombotic
complications and thromboembolic occlusions are the major
obstacles to the complete success of therapeutic procedures,
such as endarterectomy, coronary angioplasty, arterial graft-
ing and implantation of cardiovascular devices . Although the
mechanism of occlusion is multifactorial, studies performed
to date have shown that platelet deposition plays a predom-
inant role in all of these processes, and that patients under-
going cardiovascular procedures could therefore benefit
from treatment with antiplatelet agents (1-6) .
Currently, one of the most common antithrombotic strat-
egies is the administration of low dose aspirin, which irre-
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previously been labeled with hnihnn-111 Was IN dogs were
assigned to three groups: group I (n = 18) was the control group ;
group 11 (it = 12) was treated orally with 5 mg of aspirin/kg body
weight per day for 7 days before induction of thrombosis, and
group 111 (n = 10) was treated intravenously with a single dose of
P37 (U.8 mg/kg) .
Results . The indium-111 oxine activity deposited in the thrombi
was 12,94 ± 12.83% (mean ± SD) in group 1, 3.55 ± 2,99% in
group 11 and 0 .03 ± 0.03% in group 111. The differences between
groups were always statistically significant (p < 0 .05).
Conclusions.We conclude that a single dose (0,8 mg/kg) of P37
in a canine model of arterial thrombosis is -100 times more
efficient than the administration of aspirin (5 mg/kg per day) in
preventing platelet deposition during thrombus formation .
(J Am Coll cordial 994,,23.483-6)
versibly inhibits platelet-dependent cyclooxygenase, pre-
venting the production of thromboxane A2 and inhibiting the
aggregation of platelets during their entire lifetime (7) . How-
ever, there is still no available therapy to satisfactorily limit
the problems deriving from platelet activation, and the
search for a new generation of highly specific and efficient
antiplatelet agents is now a priority in the field (8) .
Methods
Monoclonal antibody production and purification . The
murine monoclonal antibody P37 of the immunogamma-
globulin-I isotype was prepared according to previously
described immunization and fusion protocols and screening
assays (9) . It was purified from ascitic fluid after sequential
25% and 50% saturated ammonium sulfate . The 50% satu-
rated ammonium sulfate precipitates were subjected to af-
finity chromatography on protein A-Sepharose (Pharmacia)
according to the manufacturer's instructions . The whole
purification process was monitored by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and enzyme im-
munoassay, as described elsewhere (10, 11) .
0735-1097/94/$7.00
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Table 1 . Percent of Indium-I I I Oxine Activity Deposited in Arterial Thrombi of Each of Three
Study Groups of Dogs With Respect to Total Injected Dose*
Experimental animals . A total of 40 adult male mongrel
dogs (10 to 15 kg) were assigned to three groups : group I (n =
18) was the control group ; group 11 (n = 12) was treated
orally with 5 mg of aspirin/kg body weight per day for 7 days
before induction of carotid artery thrombosis ; and group III
(n = 10) was treated intravenously with a single dose of P37
(0.8 mg/kg) 15 min before induction of thrombosis and after
injection of the labeled autologous platelets
Anesthetic technique . Anesthesia was induced with so-
dium pentothal (20 mg/kg) and maintained with pancuronium
bromide, fentanyl, oxygen and nitrous oxide . Mechanical
ventilation with a tidal volume of 15 to 20 ml/kg body weight
was used in all cases . At operation the dog was injected with
its own previously labeled platelets . The right femoral artery
and vein had been previously cannulated for arterial pres-
sure monitoring and for drug infusion and sample drawing,
respectively .
Platelet labeling . The method used to prepare washed
indium-Ill oxine-labeled platelets was that developed by
Thakur et at. (12) and modified by Kinlough-Rathbone et al .
(13) and Escudero et al . (3) . The volume of labeled platelets
injected into each dog was 4 .0 ± 0.1 ml (mean ± SD) .
However, the number of platelets varied among groups
(group 12,927 .1 4: 1,010.2 million ; group 112,726.5 ± 1,676.9
million; group 1113,770 .9 ± 1,651 .6 million). No significant
differences were observed among the three groups .
The total activity injected, in millions of cpm, was 71 .4
30.9 in group 1, 61 .8 ± 37.2 in group II and 71 .8 :t 20.6 in
group III. Again, no significant differences were observed .
The labeling efficiency was never <70%.
Induction of experimental thrombosis. A length of 6 to
7 cm of the right carotid artery in each dog was dissected,
and thrombus formation was induced by means of an intimal
lesion produced by applying direct current (600 AA) for
45 min, according to Salazar (14) and Escudero et al . (3) .
Removal of the thrombi and quantitation of platelet aggren
gadon In vivo . Forty-five minutes after lesion induction,
vascular clamps were placed in the areas proximal and distal
to the site of thrombus formation, and the vessel was
longitudinally cut open
. The thrombi, which adhered firmly
to the vessel wall in the area of the lesion and in no case
totally occluded the vessel, were removed and introduced
into an assay tube in an automatic solid scintillation counter
(MINAXI-gamma 5530, United Technologies Packard) for
determination of indium-111 oxine activity
. From the total
*All values were multiplied by IV . Group I = control group . Group 11 = dogs treated with aspirin, 5 mg/kg per
day . Group III = dogs receiving a single intravenous dose of P37 .
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activity of the indium- I I I oxine injected into each dog and
the activity deposited in each thrombus, the in vivo platelet
aggregation at the induction site was calculated and ex-
pressed as the percent of the total activity injected, allowing
us to compare the results within each group and between
groups. Statistical study of the data was performed with It -
nonparametric analysis of variance (Kruskal-Wallis analysis
of variance) and the Mann-Whitney U test .
Results
Experimental thrombosis. In the vascular lesion pro-
duced by direct current, corresponding to type III in the
classification proposed by Ip et al . (15), endothelial denuda-
tion is observed . The lesion penetrates the intima and the
tunica media, exposing the components of the latter layer,
particularly the fibrillar collagen, with marked platelet aggre-
gation and formation of a mural thrombus .
Antithrombotic activity of monoclonal antibody P37 in
arterial vessels. The indium-Ill oxine activity deposited in
the thrombi induced in control dogs was 12.94 ± 12 .83% of
the total activity injected . Aspirin administration (5 mg/kg
per day for 7 days) decreased the indium- I I I oxine activity
deposited in the thrombi to 3 .55 ± 2 .99%, that is, approxi-
mately fourfold compared with that in control dogs (p <
0.05) . However, a single dose of monoclonal antibody P37
(0.8 mg/kg) decreased the indium-Ill oxine activity depos-
ited in the induced thrombi to 0 .03 ± 0.03% of the total
indium-Ill oxine injected into the dogs, that is, 100 times
lower than the level found in aspirin-treated dogs (p < 0 .05)
and 400 times lower than that in control dogs (p < 0 .05)
(Table 1) .
Discussion
Glycoprotein Ilb/Illa is the most selective target known
for interfering with the platelet contribution to thrombus
formation, induced by any of the agonists known to operate
in vivo (16,17) . Thus, it has been shown that certain mono-
clonal antibodies to glycoprotein IIb/IIIa are able to de-
crease thrombus formation in animal models of experimental
thrombosis (18,19) and to speed reperfusion of thrombosed
coronary arteries, preventing reocclusion of the involved
vessels in animal models of thrombolysis (20,21) . In other
systems, monoclonal antibodies are potent inhibitors of
No. of
Observations
Mean
Value SD
Median
Value SE
Maximal
Value
Minimal
Value
Group 1 18 12.94 12 .83
9 .94 3 .02 45 .19 0.34
Group 11 12 3 .55 2.99 3 .01 0 .86 11 .62 0.55
Group 111 10 0.03 0.03 0 .02 0 .01 0 .12
0.007
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coronary artery thrombosis induced by electrical stimulation
and platelet deposition on synthetic grafts (22,23) .
Ancther line of research has followed the recognition, in
fibrinogen, of two major domains for binding to activated
glycoprotein llb/111a that are composed of the amino acid
sequences RGID and KQAGDV located at the Aalpha chain
and at the C-terminal of the gamma-chain, respectively
(16,17). It has been shown that different forms of peptides
containing any of these sequences are inhibitors, to a vari-
able extent, of in vivo platelet thrombus formation, ap-
proaching, at the highest doses, the inhibition capacity of
certain monoclonal antibodies (24-26) . A novel series of
snake venom peptides, containing the RGD sequence and
known as desintegrins, also inhibit glycoprotein llblllla
function both in vitro and in vivo (27,28) . At present, many
practical aspects remain to be resolved before glycoprotein
Jib/ilia-specific monoclonal antibodies, RGD and
KQAGDV peptides and peptidomimetics, now under devel-
opment, are ready to constitute the much desired new
generation of antithrombotic agents (29) .
In the present study, we compared the antithrombolic
activity in dogs of aspirin and the murine monoclonal anti-
body P37, which inhibits platelet aggregation and fibrinogen
binding to activated platelets and whose epitope is located in
or very near the domain of the beta-subunit of the fibrinogen
receptor (the glycoprotein Ilia 100 to 109 amino acid se-
quence), contributing to the topography of the fibrinogen
binding site or sites (9,30) . This antibody belongs to a series
of anti-glycoprotein lib and anti-glycoprotein Illa monoclo-
nal antibodies whose epitopes have been unambiguously
located (10,11) and whose functional mapping in vivo we
plan to carry out by measuring their antithrombotic activity
in the experimental model of arterial thrombosis in dogs that
we used in the present study (3,14) .
Conclusions. In a straightforward interpretation of our
results, we conclude that a single dose of the monoclonal
antibody P37, administered immediately before thrombus
formation in a canine model of carotid thrombosis, is --100
times more efficient than aspirin administration in preventing
platelet deposition . The high antithrombotic activity of this
monoclonal antibody was somewhat predictable given its in
vitro platelet antiaggregating activity and the localization of
its epitope at or very near the fibrinogen binding site in the
platelet fibrinogen receptor glycoprotein Ilb/111a or integrin
alphallbbeta3 (30) .
Future directions . As previously mentioned, a further
step might be to compare the antithrombotic activity of other
anti-glycoprotein Ilb and anti-glycoprotein Illa monoclonal
antibodies available in our laboratory . Such a comparison : a)
should establish the correlation between epitope location in
the fibrinogen receptor, for instance by studying the relation
with the fibrinogen binding site or by measuring the exposure
in rest or activated platelets or both ; and b) should determine
whether there is synergism in the antithrombotic activity of
mixtures of these monoclonal antibodies, for instance anti-
bodies to the two subunits, antibodies to the entire glyco-
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protein llb/Illa heterodimer but not to individual subunits or
antibody fragments .
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